Objective:

To explore the feasibility and outcomes of combining immunotherapy with chemotherapy in older breast cancer patients, focusing specifically on a case study of a 79-year-old woman with triple-negative breast cancer.

Key Findings:

• The patient achieved a complete pathologic response with no remaining cancer cells after treatment, highlighting the effectiveness of the combined approach in older patients.
• Lowering chemotherapy doses and administering them weekly improved tolerance and allowed for close monitoring of side effects, which is crucial for elderly patients.
• Circulating tumor cell tests showed a higher detection rate for recurrence compared to traditional tumor marker tests, indicating a need for updated testing methods in older populations.

Interpretation:

Older patients can tolerate chemotherapy combined with immunotherapy effectively when treatment is carefully managed and adjusted based on individual health conditions, as demonstrated in this case.

Limitations:

• The study is based on a single patient case, limiting generalizability to the broader population of older breast cancer patients.
• Not all oncologists may have access to advanced testing methods like circulating tumor cell tests, which could affect the monitoring of recurrence in older patients.

Conclusion:

Older patients can successfully receive combined chemotherapy and immunotherapy with proper management of treatment and side effects, as evidenced by the positive outcomes in this case study.